14 terminated. 14 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 14 | Terminated 14 |
Follow Retinal Degeneration: new trials by email Literature Review of Retinal Degeneration trials Research Report on Retinal Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment Aflibercept(BAY86-5321, Eylea) - Neovascular (Wet) Age-related Macular Degeneration | Phase 4 | Terminated | Bayer | 3 | 2023-04-25 | 2024-10-16 |
| Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Difluprednate, Nepafenac, Prednisolone acetate - Uveitis, Macular Edema | Phase 4 | Terminated | University of California, San Francisco | 9 | 2018-09-12 | 2021-01-13 |
| Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab ranibizumab - Visual Acuity Reduced Transiently, Macular Edema, Cystoid | Phase 4 | Terminated | Prof. Dr. Antonia M. Joussen | 4 | 2016-01-18 | 2019-11-20 |
| Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections Aflibercept - Age Related Macular Degeneration | Phase 4 | Terminated | Unity Health Toronto | 23 | 2014-04-17 | 2018-04-24 |
| Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision Ranibizumab, Sham injection, Rescue laser - Branch Retinal Vein Occlusion, Macular Edema | Phase 4 | Terminated | Seoul National University Bundang Hospital | 19 | 2013-01-01 | 2019-09-19 |
| Ranibizumab and the Risk of Arterial Thromboembolic Events 0.5 mg of ranibizumab, 0.5 mg of ranibizumab + photodynamic therapy, Sham injection - Age-related Macular Degeneration, Coronary Artery Disease | Phase 4 | Terminated | Ural State Medical University | 380 | 2010-06-01 | 2015-05-19 |
| Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis Methotrexate, Placebo - Sarcoid-associated Uveitis, Ocular Sarcoidosis | Phase 4 | Terminated | Assistance Publique - Hôpitaux de Paris | 7 | 2009-09-01 | 2014-06-02 |
| Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation bevacizumab - Macular Edema | Phase 4 | Terminated | Asociación para Evitar la Ceguera en México | 15 | 2008-07-01 | 2024-05-30 |
| Investigation of Macular Pigment Augmentation on Dark Adaptation ZeaVision EyePromise Restore, Multivitamin - Aging, Age-Related Macular Degeneration | Phase 4 | Terminated | University of Alabama at Birmingham | 13 | 2007-12-01 | 2010-10-27 |
| Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO bevacizumab and triamcinolone - Macular Edema, Central Retinal Vein Occlusion | Phase 4 | Terminated | Asociación para Evitar la Ceguera en México | 10 | 2007-06-01 | 2024-05-30 |
| Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration Ranibizumab (Lucentis), 0.5mg ranibizumab - Age-Related Macular Degeneration | Phase 4 | Terminated | David M. Brown, M.D. | 7 | 2007-01-01 | 2016-03-04 |
| An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD Pegaptanib Sodium 0.3 mg - Age Related Macular Degeneration (AMD), Macular Degeneration | Phase 4 | Terminated | Pfizer | 288 | 2006-07-01 | 2012-04-04 |
| A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD) Pegaptanib sodium - Macular Degeneration | Phase 4 | Terminated | Eyetech Pharmaceuticals | 262 | 2006-04-01 | 2007-01-15 |
| Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD) Photodynamic Therapy (PDT) with Visudyne (verteporfin), Macugen (pegaptanib sodium) - Age-Related Macular Degeneration | Phase 4 | Terminated | Eyetech Pharmaceuticals | 360 | 2005-03-01 | 2007-01-15 |
Macular Degeneration (8) · Macular Edema (6) · Retinal Vein Occlusion (2) · Cerebrovascular Disorders (1) · Choroidal Neovascularization (1) · Coronary Artery Disease (1) · Uveitis (1)
Eye Diseases (14) · Retinal Diseases (14) · Macular Degeneration (6) · Cardiovascular Diseases (3) · Vascular Diseases (3) · Embolism and Thrombosis (2) · Thrombosis (2) · Uveal Diseases (2) · Venous Thrombosis (2) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Choroid Diseases (1)
Ranibizumab (4) · Photochemotherapy (3) · pegaptanib (3) · 1-phenyl-3,3-dimethyltriazene (2) · Bevacizumab (2) · aflibercept (2) · Geritol (1) · Laser Therapy (1) · Methotrexate (1) · Triamcinolone (1) · Verteporfin (1) · difluprednate (1) · nepafenac (1) · prednisolone acetate (1) · salicylhydroxamic acid (1)
Asociación para Evitar la Ceguera en México (2) · Eyetech Pharmaceuticals (2) · Assistance Publique - Hôpitaux de Paris (1) · Bayer (1) · David M. Brown, M.D. (1) · Pfizer (1) · Prof. Dr. Antonia M. Joussen (1) · Seoul National University Bundang Hospital (1) · Unity Health Toronto (1) · University of Alabama at Birmingham (1) · University of California, San Francisco (1) · Ural State Medical University (1)
United States (4) · Canada (3) · France (2) · Germany (2) · Mexico (2) · United Kingdom (2) · Austria (1) · Belgium (1) · Czechia (1) · Denmark (1) · Finland (1) · Greece (1) · India (1) · Italy (1) · Netherlands (1)
Alexander Kharlamov, M.D., Ph.D. (1) · Carmen Gonzalez-Mijares, Physician (1) · David M Brown, M.D. (1) · Hugo Quiroz-Mercado, Retinologyst (1) · Jan Gabinsky, M.D., Ph.D. (1) · Juan Manuel Jimenez Sierra, Retinologyst (1) · Kyu Hyung Park, M.D. (1) · Leo P Semes, O.D. (1) · MA Martinez-Castellanos, Physician (1) · Michael H Brent, MD, FRCSC (1) · Nisha Acharya, MD MS (1) · Octavio Burgos Vejar, Physician (1) · Olga Kovtun, M.D., Ph.D. (1) · Omar Honerlager, preresident (1)